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Abstract
Background: To date, no data have been available concerning the psychometric characteristics of the
Internalized Stigma of Mental Illness scale (ISMI-29) in Latin American countries. The aim of this study was
to validate a Latin American version of the ISMI in people with schizophrenia.
Methods: The study included 253 stabilized outpatients with schizophrenia from 3 Mental Health Services
in three Latin American countries: Bolivia (N = 83), Chile (N = 85) and Peru (N = 85). We analyzed the
psychometric properties using item response and classical test theories. An item reduction was then
performed to improve the psychometric properties of the ISMI-29. The final version of the ISMI was tested
for construct validity, reliability, external validity and differential item functioning (DIF).
Results: The five-factor structure of the ISMI-29 was not confirmed using confirmatory factor analysis
(RMSEA = 0.12, CFI = 0.77, and WRMR = 2.20). Seventeen items were discarded to obtain a satisfactory
psychometric version. The ISMI-12 evaluates 3 dimensions: social stigma (4 items), stigma experience (4),
and self-stigma (3). The factor structure accounted for 68% of the total variance. Internal consistency was
satisfactory. The scalability was satisfactory, with INFIT statistics within an acceptable range. In addition, the
results confirmed the absence of DIF and supported the invariance of the item calibrations between
countries.
Conclusion: The ISMI-29 is not valid in our sample and should not be used in Latin American countries.
The ISMI-12 is the first internalized stigma questionnaire with satisfactory psychometric properties available
in Latin American countries. Its brevity could facilitate its dissemination and use in clinical settings.
Keywords: Internalized stigma, Schizophrenia, Psychometric properties, Validity
Background
People with mental illness are exposed to the nega-
tive stereotypes of the general population about
people with mental illness and may internalize them,
which yields the so-called internalized stigmas [1, 2].
The findings of a systematic review by Gerlinger and
colleagues [3] indicate that from one-third to one-
half of patients with schizophrenia (SZ) feels shame,
embarrassed, guilty, and inferior to those without
mental illness [4–7]. Also, as a consequence of the
disorder, patients with internalized stigma are more
likely to experience depression, reduced self-esteem,
reduced recovery orientation, reduced empowerment,
and increased perceived devaluation and discrimin-
ation [8–12]. Self-stigma is a barrier for early anti-
psychotic treatment onset and appropriate treatment
in general, because the patients tend to lose their
motivation to receive medical health care [13–16].
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Another consequence is the increased duration of
untreated psychosis has been associated with worse
prognosis and also with higher hospitalization, involuntary
admission and suicidal behaviour [17]. These last elements
impact on the therapeutic effect, because, as Chang and
colleagues [18] pointed out is expected to have better out-
comes when health care professionals take into not only
the symptomatology but also self-stigma in persons with
mental illness [16, 18, 19].
However, the consequences of self-stigma do not only
affect the patient, but also the caregiver. This type of
stigma is called “courtesy stigma”, being stigmatized be-
cause of one’s relationship to a person with a stigmatiz-
ing mark [18, 20, 21] and “affiliate stigma”, internalizing
the stigma because of the relationship that affects the
caregiver’s self-esteem and burden [7, 20, 22, 23].
Accurate and appropriate assessment of internalized
stigma is thus critical to reduce duration of untreated
psychosis to improve medical-social programs and to
guide public health policies for SZ people. The Inter-
nalized Stigma of Mental Illness scale (ISMI-29) is one
of the most widely used measurements of internalized
stigma in mental health research [11, 24–26]. There is
only one validation in Spanish, but it was carried out in
Spain, whose version obtained good values of internal
consistency and test-retest reliability, for the total score
of the scale (0.91 and 0.95 respectively), as well as for
the five subscales, except for the Stigma Resistance sub-
scale (Cronbach’s alpha 0.42) [27]. To date, the psycho-
metric characteristics of the ISMI-29 have not been
explored in Latin American countries [9]. Even though,
the language is similar, we cannot exclude substantial
socio-cultural and economic differences between Spain
and Latin American countries, influencing the phenomenon
of stigmatization. In addition, the previous study did not re-
port how the factorial structure described in their samples
fit the initial structure of the tested instrument, which re-
mains a key point when considering validity. Restricted data
regarding validity and reliability were also provided. For
these reasons, the extent to which SZ patients in Latin
American countries can validly self-report their internalized
stigma using the ISMI-29 is a crucial issue that has not
been sufficiently explored. Furthermore, shortening the
ISMI-29 could make the assessment on internalized stigma
efficiently.
The aims of this study were thus to validate a Latin
American version of the ISMI in people with schizo-
phrenia and to shorten the ISMI-29 into a brief measure
to efficiently measure internalized stigma.
Methods
Study participants
Overall, 253 stabilized SZ outpatients were consecu-
tively recruited between May 2012 and February
2013 in the three public ambulatory psychiatric care
centers of three areas: Arica, northern Chile (N = 85,
33.6%), Tacna, southern of Peru (N = 85, 33.6%), and
La Paz, Central-Western of Bolivia (N = 83, 32.8%).
The three centers shared similar characteristics in
terms of size, type of treatment delivered to pa-
tients, professionals and free access of care.
Inclusion criteria
All stabilized community-dwelling patients diagnosed
with schizophrenia according to the criteria of Inter-
national Classification of Diseases (ICD), 10th version
[28] were included in this study.
Exclusion criteria
Patients with history of neurological disorders (including
stroke, epilepsy and head injury) or all illnesses affecting
central nervous system were not included in the present
study.
Procedures
The study was approved by the Ethics Committee of
the University of Tarapacá and the National Health
Service of Chile. Two psychologists, who were part
of the research team, trained for scale evaluation,
and supervised by the principal researcher (AC-U),
conducted the evaluations of the participants under
the auspices of the mental health services of each
country. The length of time of the evaluation was
between 20 and 30 min.
Before the start of the survey, written informed con-
sent was requested and received from the patient. The
objectives of the study were explained as well as the vol-
untary nature of participation. No compensation was of-
fered for participating in the study.
Data collection
Recruitment process
At each center, during a three- month window, all
patients were invited to participate as they came for
their monthly follow-up visits. The overwhelming
majority of the patients agreed to participate.
Demographic and illness characteristics variables
Age, gender, ethnicity (Aymara and non-Aymara),
educational level (≥ 12 years or < 12), employment
status (unemployed or employed), family income
(measure of the total salary per month for all mem-
bers of the family, expressed in US dollars), age at
onset the disorder, the number of hospitalizations in
the last 3 years were reported. All patients were ad-
ministered antipsychotics. The presence or absence
of add-on integrated treatment (defined by psycho-
therapy, family psychoeducation, and/or day care
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hospital in addition to pharmacological treatment)
was also reported.
Concerning ethnicity, the Aymara is the largest
ethnic group in the region, with a population of 2
million people, and has lived in the Andes Moun-
tains for centuries. Recent generations of Aymara
have undertaken a massive migration from rural
towns to large cities and, thus, receive healthcare
services from the same clinics as non-Aymara indi-
viduals [29–31]. This ethnic group share a particular
worldview were the concept of mental health disorder is
understood according to this worldview. Therefore, al-
though there are differences in socioeconomic terms be-
tween countries, there are a number of cultural traditions
that unify them.
Instruments
Internalized stigma [11].
The ISMI scale is a self-rated assessment of the
subjective experience of stigma for people with
mental illnesses that comprises 29 items across five
subscales: alienation (6 items), stereotype endorse-
ment (7 items), discrimination experience (5 items),
social withdrawal (6 items), and stigma resistance (5
items). The alienation measures the subjective ex-
perience of being less than a full member of society
or having a ‘spoiled identity’. The stereotype en-
dorsement measures the degree to which respon-
dents agree with common stereotypes about people
with mental illness, such as ‘mentally ill people tend
to be violent’ and ‘I can’t contribute anything to so-
ciety because I have a mental illness.’ The discrim-
ination experience subscale intends to capture
respondents’ perception of the way that they cur-
rently tend to be treated by others, such as ‘People
ignore me or take me less seriously just because I
have a mental illness’ and ‘People discriminate
against me because I have a mental illness.’ The so-
cial withdrawal contains items, such as ‘I don’t talk
about myself much because I don’t want to burden
others with my mental illness’ and ‘I avoid getting
close to people who don’t have mental illness to
avoid rejection.’ The Stigma Resistance intends to
portray the experience of resisting or being un-
affected by internalized stigma [11].
Each item is rated on a 4-point Likert scale ranging
from 1 = strongly disagree to 4 = strongly agree with
higher scores indicating higher internalized stigma.
Each score is calculated by adding the item scores to-
gether and then dividing by the total number of an-
swered items. A high total score on the ISMI scale
indicates more severe internalized stigmatization. The
Spanish version of the ISMI-29 was used in this work
[27]. Following the method used by Lysaker and
colleagues [25], 4 categories can be created for each
score: 1.00–2.00 (minimal to no internalized stigma),
2.01–2.50 (mild internalized stigma), 2.51–3.00 (mod-
erate internalized stigma), and 3.01–4.00 (severe inter-
nalized stigma). Following the method used by Ritsher
& Phelan [7], 2 categories can also be created for each
score: 1.00–2.50 (does not report high internalized
stigma), and 2.51–4.00 (reports high internalized
stigma).
Positive and Negative Syndrome scale for Schizophrenia
(PANSS) [32].
This 30-item, 7-point (1–7) rating scale has been
specifically developed to assess psychotic symptoms
in SZ individuals with five factors (positive, negative,
cognitive, depressive and excitement subscores). The
PANSS has been translated and validated in Spain by
Peralta and Cuesta [33] and in Mexico by Fresán,
et al. [34]. The psychometric properties were satis-
factory with principal component analysis explaining
53.4% of the total variance and Cronbach’s alpha >
0.8 for each dimension [34]. This scale was adminis-
tered by the treating health professionals.
Schizophrenia Quality of Life Questionnaire (SQoL18) [35].
Quality of life (QoL) was assessed using the SQoL18,
a self-administered QoL questionnaire designed for
people with schizophrenia [35] and validated in Latin
America [36]. QoL score ranges from 0, indicating
the lowest QoL, to 100, the highest QoL. Factor ana-
lysis performed in the 3 countries (Bolivia, Chile and
Peru) showed that the questionnaire’s structure ad-
equately matched the initial French structure of the
SQoL18. The unidimensionality of the dimensions
was preserved, and the internal/external validity indi-
ces were close to those of the reference population
[36].
Statistical analysis
Socio-demographic and clinical characteristic descrip-
tions were done with frequencies and percentages for
categorical variables and with means and standard devia-
tions for continuous variables.
The 5-factor structure of the ISMI-29 was verified
using confirmatory factor analysis (construct validity).
In this confirmatory factor analysis, we used the diag-
onally weighted least squares (DWLS) method to esti-
mate the coefficients and fit indices. The following
indicators were required to confirm that this structure
match with our data. The Root Mean Square Error of
Approximation (RMSEA) is acceptable if < 0.08, the
Comparative Fit Index (CFI) is higher than 0.9, and
the Weighted Root Mean Square Residual (WRMR) (a
fit index generated from the use of DWLS) is lower
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than 0.9. Considering previous validation studies in
different countries [9], we hypothesized that the 5-
factor structure initially developed would not fit with
our data. In this case, the following reduction proced-
ure will be applied.
The construct validity was assessed using principal
component factor analyses with varimax rotation
[37], in order to determine a new structure and the
number of independent dimensions of internalized
stigma. Eigenvalues greater than or equal to 1 were
retained [38]. Descriptive statistics were performed
to examine the response distribution to each item
and dimension. The items with the following char-
acteristics were removed: low response rate (< 20%),
low index discrimination (< 0.70), decrease of cron-
bach’s alpha coefficients, and multiple loading (>
0.4) of an item on several factors [39]. Once the
structure and the number of items are fixed, this
final version was tested for construct validity, reli-
ability, external validity and acceptability.
Item-internal consistency (IIC) was assessed by cor-
relating each item with its scale (corrected for overlap)
using Pearson’s coefficient (correlation of 0.4 recom-
mended for supporting item-internal consistency)
[40]; item discriminant validity was assessed by deter-
mining the extent to which items correlate more
highly with the dimensions they are hypothesized to
represent than with the other ones [41]. For each di-
mension scale, internal consistency reliability was
assessed by Cronbach’s alpha coefficient (coefficient of
at least 0.7 expected for each scale [40].
The uni-dimensionality of each dimension was
assessed using Rasch analysis. The goodness-of-fit
statistics inlier-sensitive mean square (infit MnSq),
ranging between 0.7 and 1.3 ensured that all items of
the scale measured the same concept. Floor and ceil-
ing effects were reported assessing the homogeneous
repartition of the response distribution. Differential
item functioning (DIF) analyses were performed,
which compared the item differences between groups
of individuals according to socio-demographic param-
eters (gender, ethnicity, and country) to check
whether all items behave the same way [42]. The DIF
means that an item performs and measures differently
for one subgroup of a population than for the other.
The external validity was assessed by studying rela-
tions between dimensions of ISMI scores and demo-
graphic, illness and QoL characteristics. The underlying
assumption was that stigma was associated with being a
man and Aymara, lower family income, higher psy-
chologic symptoms and lower quality of life [43].
We also explored the relations between the new
version of ISMI and ISMI-29 scores. The underlying
assumption was that total and dimension scores of
the new ISMI would be highly correlated with
ISMI-29 and also more correlated with scores of
similar dimensions.
All the tests were two-sided. Statistical signifi-
cance was defined as p < 0.05. The statistical ana-
lyses were performed using the SPSS version 20.0
software package (SPSS Inc., Chicago, IL, USA) and
Mplus Software.
Results
Sample characteristics
Two hundred and fifty-three SZ patients were enrolled
in this study. The sociodemographic and clinical features
are listed in Table 1.
Table 1 Socio-demographic and clinical characteristics of the
study sample (N = 253)
Patients Mean ± SD, median [IQR] or n (%)*
Age in years 35.6 ± 12.5
Gender
Women 83 (33.6)
Men 164 (66.4)
Ethnicity
Non-Aymara 136 (53.8)
Aymara 117 (46.2)
Educational level
≥ 12 years 40 (15.8)
< 12 years 213 (84.2)
Employment status
With employment 78 (31.2)
Without employment 172 (68.8)
Monthly family income (US dollars) 331.3 [144.9; 517.9]
Age at onset of the disease 20.9 ± 6.4
Number of hospitalizations 1 [2; 0]
Type of mental health treatment
Integrated 31 (12.3)
Only pharmacological 222 (87.7)
Symptoms severity
PANSS total score 71.3 ± 28.2
Positive factor 8.3 ± 4.6
Negative factor 18.6 ± 8.4
Depressive factor 6.4 ± 3.7
Cognitive factor 7.3 ± 4.0
Hostile-excitement factor 11.5 ± 5.9
Quality of life
S-QoL 18 index 54.3 ± 14.4
*Mean ± SD: mean ± standard deviation; median [IQR]: median [Inter Quartile
Range]; n (%): effective (percentage)
PANSS Positive and Negative Syndrome scale for Schizophrenia
S-QoL18 Schizophrenia Quality of Life questionnaire
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Construct validity of the ISMI-29
The five-factor structure of the ISMI-29 was not con-
firmed using confirmatory factor analysis: RMSEA =
0.12, CFI = 0.77, and DWLS = 2.20. Cronbach’s alpha
coefficients were not satisfactory (discrimination ex-
perience = 0.47, social withdrawal = 0.68, and stigma
resistance = 0.67), except for two dimensions (alien-
ation = 0.73, and stereotype endorsement = 0.72).
Item reduction of the ISMI-29
Seventeen items were discarded for the following rea-
sons: 5 items for low index discrimination, 12 items
were deleted after examination of items’ structure
using the principal component analyses (4) and Cron-
bach’s alpha coefficients (8). The final version con-
tained 12 items (ISMI-12).
Construct validity, internal structural validity and
reliability of the ISMI-12
The results are summarized in Table 2. The structure
of the ISMI-12 was confirmed by principal compo-
nent factor analysis, identifying a 3-factor structure
accounting for 68% of the total variance. The dimen-
sions were named according to their constitutive
items: social stigma (4 items), stigma experience (4
items), and self-stigma (3 items). The 12 items are de-
tailed in the Appendix. Internal consistency was satis-
factory for all dimensions: each item achieved the
0.40 standard for item-internal consistency. The cor-
relation of each item with its contributive dimension
was higher than with the others (item discriminant
validity). Floor effect ranged from 16.6 to 27.9% and
ceiling effect from 19.5 to 29.2%. Cronbach’s alpha
coefficients ranged from 0.77 to 0.88, indicating satis-
factory internal consistency. The overall scalability
was globally satisfactory: no items showed an infit
MnSq outside the acceptable range except for 2 items
and country. Dimension and index scores was then
calculated. The results also confirmed the absence of
DIF according to gender, ethnicity, and country and
supported the invariance of the item calibrations.
According Lysaker, et al., (2007) [25], 23.4% (57) of
individuals had minimal to no internalized stigma,
27.0% (66) had mild internalized stigma, 25.0% (61)
had moderate internalized stigma, and 24.6 (60) had
severe internalized stigma. Following the method
used by Ritsher & Phelan, 2004 [24], 50.4% (123) did
not report high internalized stigma, and 49.6% (121)
reported high internalized stigma.
External validity of the ISMI-12
The results are summarized in Table 3. Higher
psychotic symptomatology, lower quality of life, and
lower family income were associated with internal-
ized stigma. Men had higher social withdrawal than
women, Aymara had higher alienation than non-
Aymara, and employment was associated with lower
internalized stigma.
The correlations between the scores of ISMI-12
and ISMI-29 are presented in Table 4. All the di-
mensions were significantly correlated (r ranged
from 0.18 to 0.97). The total scores of ISMI-12 and
ISMI-29 were highly correlated (r = 0.93). The 3 di-
mensions of the ISMI-12 (i.e., social stigma, stigma
experience, and self-stigma) were highly correlated
with three similar dimensions of the ISMI-29 (social
withdrawal r = 0.98, discrimination experience r =
0.97, and alienation r = 0.92).
Acceptability
The proportion of missing values per dimension never
exceeded 1.0%.
Discussion
In this study, we have demonstrated the validity and
reliability of ISMI-12 in a large multicenter sample of
Table 2 Dimension characteristics of the ISMI
Dimension/index
(number of items)
M (SD) Missing
values
%
Item-internal
consistency
(min-max)
Item discriminant
validity
(min-max)
Floor
%
Ceiling
%
Alphaa INFITb
(min-
max)
Dimension 1: social stigma (4) 2.8
(0.9)
0.8 0.67–0.77 0.24–0.46 16.6 29.2 0.88 0.82–1.25
Dimension 2: stigma experience
(4)
2.5
(0.8)
0.6 0.55–0.61 0.32–0.44 24.3 19.5 0.77 0.85–1.08
Dimension 3: self-stigma (3) 2.4
(1.0)
0.7 0.67–0.75 0.24–0.47 27.9 21.9 0.85 0.87–1.19
Index (12) 2.6
(0.7)
0.7 NAc NAc NAc NAc 0.88 NAc
aCronbach’s Alpha, bRasch’s statistics, cNA Not Applicable
M (SD) mean (standard deviation); a higher score represents a higher level of unawareness
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Table 3 External validity of the ISMI dimension scores and index
Dimension 1: social stigma Dimension 2: stigma experience Dimension 3:
self-stigma
Index
Symptoms severity
PANSS total score 0.26** 0.33** 0.24** 0.33**
Positive factor 0.24** 0.30** 0.22** 0.30**
Negative factor 0.31** 0.24** 0.18** 0.30**
Depressive factor 0.18** 0.26** 0.19** 0.27**
Cognitive factor 0.13* 0.27** 0.22** 0.23**
Hostile-excitement factor 0.01 0.18** 0.13* 0.12
Quality of life
S-QoL 18 index −0.38** −0.47** −0.42** −0.51**
Age (years) 0.08 0.11 −0.07 0.04
Monthly family income (US dollars) −0.21** − 0.11 −0.14* − 0.21**
Age at onset of the disease (years) −0.02 − 0.07 −0.04 − 0.07
Number of hospitalizations 0.09 0.04 0.02 0.05
Gender
Men 2.9 (0.8) 2.4 (0.8) 2.4 (1.0) 2.6 (0.7)
p-value 0.009 0.499 0.865 0.303
Ethnicity
Aymara 2.8 (0.9) 2.5 (0.7) 2.6 (0.9) 2.7 (0.7)
p-value 0.220 0.590 0.011 0.072
Education level
< 12 years 2.8 (0.9) 2.5 (0.8) 2.5 (1.0) 2.6 (0.7)
p-value 0.177 0.106 0.068 0.062
Employment status
With employment 2.5 (0.9) 2.2 (0.8) 2.2 (0.9) 2.3 (0.7)
Without employment 2.9 (0.8) 2.6 (0.8) 2.5 (1.0) 2.7 (0.7)
p-value 0.001 0.001 0.016 < 0.001
Mental health treatment
Only pharmacological 2.8 (0.9) 2.4 (0.8) 2.4 (1.0) 2.6 (0.7)
p-value 0.630 0.460 0.354 0.803
PANSS Positive and Negative Syndrome scale for Schizophrenia
S-QoL18 Schizophrenia Quality of Life questionnaire
Bold values p < 0,05, *p < 0.05, **p < 0.01
Table 4 Correlations between the scores of ISMI-12 and ISMI-29
ISMI-12
ISMI-29
Dimension 1:
social stigma
Dimension 2: stigma experience Dimension 3:
self-stigma
Index
Alienation .439** .616** .921** .787**
Stereotype endorsement .346** .522** .580** .574**
Discrimination experience .546** .972** .522** .836**
Social withdrawal .983** .535** .352** .832**
Stigma resistance .176** .343** .315** .312**
Total .700** .800** .739** .930**
*p < 0.05, **p < 0.01
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Latin American community-dwelling SZ patients from
three countries. The ISMI-12 presents interesting
characteristics for a widespread use in SZ patients in
Latin America.
Although the literature shows several instruments
of self-stigma measurement, within which some
shorter scales are observed such as the ISMI-10 [12],
the ISMI-9 [44, 45] and the Self-Stigma Scale-Short
(SSS-S, 9 items) [46, 47] and others more extensive
scales including the Self-stigma of Mental Illness
Scale (SSMIS, 40 item) [48], the Self-stigma of mental
Illness scale short form (SSMIS-SF, 20 items) [49];
the Consumer Experiences of Stigma Questionnaire
(CESQ, 20 items) [50], the Depression Self-stigma
Scale (DSSS, 32 items) [51], the Stigma Scale (SS, 28
items) [52], the Discrimination and Stigma Scale
(DISC, 36 items) [53, 54], the ISMI-12 is the only
short scale that has been valid in a Latin American
context. According to several authors, a short form of
a scale is frequently associated with better acceptabil-
ity [55]. The average completion time is expected to
be less than 5 min and this will facilitate its use in
routine clinical practice.
The internal structure retrieved several important
dimensions of stigma for patients. The classification
of the items is different from that of the ISMI-29 and
may add a complementary approach to this scale.
This new classification appears transversal to the dif-
ferent dimensions (i.e., alienation, stereotype endorse-
ment, discrimination experience, social withdrawal
and stigma resistance) of the ISMI-29 (trans-dimen-
sional), with a grouping more centred on the patient’s
experience rather than on a theoretical and concep-
tual approach of the stigma. The first dimension ad-
dresses the social aspect of stigma while the ISMI-29
focused on social withdrawal. In this dimension (i.e.,
social stigma), items explored social dependency
(item 1), social withdrawal (item 2 and 3), and social
exclusion (items 4 and 5). Previous studies reported
the importance of the social issue in the phenomenon
of stigmatization: social anxiety, social withdrawal,
and lower social functioning [3]. The second dimen-
sion is about experience of stigma including items
discrimination (items 6, 7 and 9) and negative belief
about the self (item 8). Previous studies reported the
closely link between discrimination and the impact on
self-esteem and stereotype [1]. The third dimension is
related to self-stigma in accordance with the defin-
ition proposed by Corrigan and Watson (2002) [1]: an
“internalisation of public stigma” or as “the product of
internalization of shame, blame, hopelessness, guilt
and fear of discrimination associated with mental ill-
ness”. Lastly, we can also note that the majority of
items on stigma resistance were discarded, confirming
that stigma resistance do not function like a subdi-
mension of internalized stigma of mental illness con-
struct [56].
Concerning the psychometric properties, our pro-
posal meets standards. The internal structure was
supported by a high internal consistency. Internal
consistency reliabilities for the three dimensions
were shown to be high (Cronbach’s alpha> 0.77). Ex-
ternal validity, explored by the use of demographic,
illness and QoL characteristics confirmed results of
previous works on stigma. As expected, patients
with higher psychotic symptoms had higher scores
of stigmatization. Like other studies, a number of
reasons are raised in relation to this point: thus, the
greater the number of symptoms, the more likely it
is to be the target of stigma from others, which
would increase the probability of greater self-stigma,
being more difficult for the patient to formulate
positive beliefs about them. Conversely, if the pa-
tient has a lower internalized stigma, he / she is
likely to be able to manage the symptoms more ef-
fectively, reducing its severity [25]. Higher scores of
stigmatization were associated with lower quality of
life. This result is consistent with previous studies
showing reduced subjective quality of life mediated
by perceived stigma and low self-esteem in SZ sub-
jects [4, 57–60].
There are several limitations of this study. The
sample may not be representative of the entire
population of SZ patients (only public sector in
medium–large cities) and more globally of the entire
population in Latin America. Moreover, the patients
in the study sample were mostly middle-aged males
with mild disease severity and long illness duration.
Confirmation is required for more miscellaneous
and larger groups of patients. In particular, further
work is needed to test the ISMI-12 in other import-
ant South American countries like, Colombia and
Venezuela. Future studies should incorporate pa-
tients from the private sector given the marked so-
cial differences especially in Latin America. The
“responsiveness” or “sensitivity to change” defined
as the ability to detect a meaningful change, is a
core psychometric property of a measuring instru-
ment that we did not explore in this study. Its
examination is required in future studies using lon-
gitudinal data collection.
Conclusion
The ISMI-12 is the first internalized stigma question-
naire with satisfactory psychometric properties avail-
able for SZ individuals in Latin American countries.
Its brevity may be appropriate and useful for research
and clinical practices.
Caqueo-Urízar et al. Health and Quality of Life Outcomes          (2019) 17:175 Page 7 of 10
Abbreviations
CESQ: Consumer Experiences of Stigma Questionnaire; CFI: Comparative Fit
Index; DIF: Differential item functioning; DISC: Discrimination and Stigma
Scale; DSSS: Depression Self-stigma Scale; DWLS: Diagonally Weighted Least
Squares; ICD: International Classification of Diseases; IQR: Inter Quartile
Ranget; ISMI: Internalized Stigma of Mental Illness scale; PANSS: Positive and
Negative Syndrome scale for Schizophrenia; QoL: Quality of Life;
RMSEA: Root Mean Square Error of Approximation; SQoL18: Schizophrenia
Quality of Life Questionnaire; SS: Stigma Scale; SSMIS-SF: Self-stigma of
mental Illness scale short; SZ: Schizophrenia; WRMR: Weighted Root Mean
Square Residual
Acknowledgements
This research was funded in part by the Universidad de Tarapacá through
Proyecto Mayor de Investigación Científica y Tecnológica UTA n°3732-16.
Authors’ contributions
Conception and design: AC-U, LB, GF and AU. Data collection and analysis of
data: AC-U, AU, AL, MB, GF and LB. Interpretation of data: AC-U, AL, MB, LB,
GF and AU. Drafting and writing the manuscript: AC-U, AL, MB, LB, GF and
AU. All authors read and approved the final manuscript.
Funding
This research was funded by Proyecto UTA-Mayor 3732–16.
Availability of data and materials
The datasets generated and/or analysed during the current study are not
publicly available due Government policy but are available from the
corresponding author on reasonable request.
Ethics approval and consent to participate
Before the start of the study, written informed consent was requested and
received from the patient and her/his primary caregiver. The objectives of
the study were explained as well as the voluntary nature of participation. No
compensation was offered for participating in the study. The study was
approved by the Ethics Committee of the University of Tarapacá and the
National Health Service of Chile.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interest.
Author details
1Instituto de Alta Investigación, Universidad de Tarapacá, 1520 Antofagasta,
Arica, Chile. 2Universidad Católica del Norte, Avda. Angamos, 0610
Antofagasta, Chile. 3Aix-Marseille Univ, EA 3279 – Public Health, Chronic
Diseases and Quality of Life - Research Unit, 13005 Marseille, France.
Appendix
Table 5 Latin American version of the ISMI: ISMI-12
Items ISMI-12 (English) Items ISMI-12 (Spanish) Corresponding item
in the ISMI-29
Dimensions
1. Because I have a mental illness, I need
others to make most decisions for me.
Debido a que tengo una enfermedad mental,
necesito que los demás tomen la mayoría de
decisiones por mí
Item 19 Dimension 1: social stigma
2. I stay away from social situations in
order to protect my family or friends
from embarrassment.
Me mantengo apartado de situaciones sociales
con el fin de no avergonzar a mi familia o amigos
Item 20 Dimension 1: social stigma
3. People without mental illness could
not possibly understand me.
Las personas sin enfermedad mental no
pueden entenderme
Item 21 Dimension 1: social stigma
4. People ignore me or take me less
seriously just because I have a
mental illness.
La gente me ignora o me toma menos en
serio sólo porque tengo una enfermedad mental
Item 22 Dimension 1: social stigma
5. Living with mental illness has made
me a tough survivor.
Vivir con una enfermedad mental me ha hecho
una persona fuerte
Item 24 Dimension 1: social stigma
6. I feel comfortable being seen in
public with an obviously mentally
ill person.
Me siento cómodo si me ven en público con
una persona que es evidente que tiene
enfermedad mental
Item 14 Dimension 2:
discrimination stigma
7. People often patronize me, or treat
me like a child, just because I have a
mental illness.
La gente a menudo tiene una actitud
paternalista conmigo, o me trata como a
un niño, solo porque tengo una
enfermedad mental
Item 15 Dimension 2:
discrimination stigma
8. I am disappointed in myself for
having a mental illness.
Estoy decepcionado conmigo mismo por tener una
enfermedad mental
Item 16 Dimension 2:
discrimination stigma
9. People can tell that I have a mental
illness by the way I look.
La gente puede decir que tengo una
enfermedad mental por mi aspecto
Item 18 Dimension 2:
discrimination stigma
10. I avoid getting close to people who
don’t have a mental illness to
avoid rejection.
Evito relacionarme con personas que no
tienen enfermedad mental para evitar
el rechazo
Item 4 Dimension 3: self-stigma
11. I am embarrassed or ashamed
that I have a mental illness.
Estoy avergonzado de tener una
enfermedad mental
Item 5 Dimension 3: self-stigma
12. Mentally ill people shouldn’t
get married.
Las personas con enfermedad mental
no deberían casarse
Item 6 Dimension 3: self-stigma
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